Q1 Earnings Forecast for NTLA Issued By William Blair

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Research analysts at William Blair issued their Q1 2026 earnings per share estimates for Intellia Therapeutics in a research report issued on Wednesday, March 26th. William Blair analyst M. Minter expects that the company will post earnings of ($1.12) per share for the quarter. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. William Blair also issued estimates for Intellia Therapeutics’ Q3 2026 earnings at ($1.28) EPS and Q4 2026 earnings at ($1.35) EPS.

A number of other research analysts have also recently commented on NTLA. Truist Financial cut their target price on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Morgan Stanley lowered shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $56.00 to $11.00 in a research note on Monday, January 27th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. Citigroup boosted their price objective on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Finally, The Goldman Sachs Group restated a “sell” rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research note on Friday, February 28th. Two analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.56.

Intellia Therapeutics Trading Up 1.1 %

Shares of NASDAQ:NTLA opened at $8.40 on Thursday. Intellia Therapeutics has a 12 month low of $8.11 and a 12 month high of $28.23. The company has a market capitalization of $869.54 million, a price-to-earnings ratio of -1.54 and a beta of 1.97. The firm’s 50-day moving average is $10.01 and its 200 day moving average is $13.90.

Insiders Place Their Bets

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. purchased a new position in shares of Intellia Therapeutics in the 4th quarter valued at about $25,000. Sterling Capital Management LLC increased its position in shares of Intellia Therapeutics by 866.2% in the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock valued at $37,000 after buying an additional 2,867 shares in the last quarter. Whipplewood Advisors LLC purchased a new stake in shares of Intellia Therapeutics in the fourth quarter valued at approximately $40,000. Resona Asset Management Co. Ltd. acquired a new position in shares of Intellia Therapeutics during the 4th quarter worth approximately $43,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Intellia Therapeutics by 140.9% during the 4th quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock valued at $45,000 after buying an additional 2,280 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.